Dear Spinal Cord reader You may have noticed that, in the last issue, the new editorial board has been presented. This change was made after ample consultation. It is normal that at regular intervals an important body such as an editorial board is updated in order to guarantee an efficient and high-quality review process. All board members have taken the engagement to help, in a very active way, to further improve the review process and help shorten the time before final acceptance. We also decided to create an emeritus board with senior ISCOS members who continue to provide substantial help in reviewing and advising. Many thanks to all for their willingness to be on the board and their dedication to Spinal Cord. This month's issue contains a systematic review by Wilt et al. on the effectiveness and adverse effects of botulinum toxin (BTX) in urinary incontinence (UI) owing to detrusor overactivity (DO). Randomized controlled trials (RCTs) published in English before November 2006 were included if they enrolled subjects with UI caused by DO and reported incontinence outcomes. The use of BTX has become a hot topic in scientific literature in many domains. The industry has set up a large number of sponsored trials that help us understand more and more about when and how to use it. On PubMed almost 300 reports can be found of which 10 manuscripts were published in the first period of 2007. The use of BTX has become standardized practice rather quickly in many centres. Spinal Cord was one of the first to publish the possible side effects, such as temporary generalized muscular weakness (Spinal Cord 2002; 40: 599-600) and a more general review on this topic (Spinal Cord 2005; 43: 397-399). In this age of very fast clinical use of new techniques and drugs, it is important to give full attention to the less favourable effects. But complications do seem to be rare with BTX and are mentioned only occasionally in subsequent reports. You can read the conclusion in the review published in this issue.
